CSCO 2016 第三届北京黑色素瘤国际研讨会院所动态

CSCO 2016 第三届北京黑色素瘤国际研讨会

通知公告 2016-10-11

Welcoming

On behalf of Peking University cancer hospital and CSCO (Chinese Society of Clinical Oncology), we are pleased to invite you to the 2016 CSCO 3rd Beijing international Melanoma Congress, to be held in Beijing on Oct 22-23, 2016.

This conference will provide a highly interactive forum in which leading experts and clinical researchers in the field of melanoma can discuss recent advances in clinical trial data and scientific research. This blend of clinical and scientific research with clinical practice will offer the unique opportunity for participants to be updated on all aspects of melanoma research. Lectures and Panel discussions will highlight important developments in the field, including emerging therapies and implementation of new treatment strategies. We are certain you will gain valuable insight into the current status of preclinical melanoma research and the application of new trial data into clinical practice to ultimately improve patient care.

We look forward to welcoming you to the 2016 CSCO 3rd Beijing international Melanoma Congress. We hope that you will also enjoy the beauty and culture of Beijing.

Sincerely,

QQ图片20161011131209.jpg QQ图片20161011131220.jpg

Jun Guo, MD, PhD Chair Keith T.Flaherty, MD Chair

Friday, Oct21, 2016
1:00pm–8:00pm	Registration; Lobby in New Yunnan Hotel Beijing
Saturday,OCT 22, 2016
7:00am-8:30am	Registration & Breakfast
8:30am-9:00am	Welcome and Introductions Prof. Zhan Qimin (President of Peking University Health Science Center,CHN) Prof. Sun Yan (Cancer Hospital Chinese Academy of Medical Sciences, CHN) Prof. Qin Shukui (Vice Chairman of Chinese Society of Clinical Oncology, CHN)
Keynote Lecture 　　　　Host: Prof. Qin Shukui (Bayi Hospital of PLA, Nanjing,CHN) 　　　　　　　　Prof. Liang Jun (Peking University International Hospital,CHN)
9:00am–9:30am	The Melanoma Treatment Landscape and Lessons from the Lab Georgina Long, MD (University of Sydney, Melanoma Institute of Australia,AUS)
9:30am–10:00am	Optimizing the immunotherapy /targeted therapy combinations Keith T. Flaherty, MD （Massachusetts General Hospital Cancer Center，USA）
10:00am–10:10am	Coffee & Tea
Session 1: Neoadjuvant and adjuvant therapy of melanoma 　　　Host: Prof. Liu Weifeng (Beijing Jishuitan hospital, CHN) 　　　　　　Prof. Li Hang(Peking University First Hospital,CHN)
10:10am-10:30am	Perspectives on earlier use of drugs with demonstrated activity at late stage Alexander Eggermont,MD,PhD(Institut de cander ologie GustaveRoussy, FR)
10:30am–10:50am	The landscape of adjuvant therapy: where are we now Sanjiv Agarwala (Temple University School of Medicine, USA)
10:50am–11:10am	Update of results on adjuvant trials Helen Gogas, MD (University of Athens, GRE)
11:10am–11:40am	Question & Panel Discussion All attendees
Satellite Meeting 12:00-13:00	1-MSD Company 2-BMS Company

Session 2: Immunotherapy 　　　　Host: Prof. Lin Tongyu (Sun Yat-Sen University Cancer Hospital, CHN) 　　　　　　　　Prof. Tao Min (The 1st affiliated hospital of Soochow university, CHN)
1:30pm-1:50pm	Lessons from the KEYNOTE 001 pembrolizumab trial Richard Kefford PhD, (University of Sydney, Melanoma Institute of Australia, AUS)
1:50pm-2:10pm	Immunotherapy for melanoma: current clinical advances Omid Hamid, MD（Angeles Clinic and Research Institute, Los Angeles, USA）
2:10pm-2:45pm	Interpreting the results of melanoma immunotherapy trials Merrick Ross, MD, (MD Anderson Cancer Center, USA)
2:45pm-3:05pm	Biomarkers of response to immunotherapy: are we close to clinical implementation? Caroline Robert, MD ( Institut de canderologieGustaveRoussy, FRA)
3:05pm–3:25pm	Sequential versus combination of immunotherapy and targeted therapy Steven O’Day, MD (John Wayne Cancer Institute, USA)
3:25pm-3:35pm	Coffee & Tea
Session 3: Targeted Therapy 　　　　Host: Prof. Lu Aiping(Peking University cancer hospital, CHN) 　　　　　　　　Prof. Wu Di (The First hospital of Jilin University, CHN)
3:35pm–3:55pm	Signal transduction pathways in melanoma Jeffery Sosman, MD (Vanderbilt-Ingram Cancer Center, USA)
3:55pm–4:15pm	Potential targets in acral and mucosal melanoma Jun Guo, MD, PhD ( Peking University Cancer Hospital, CHN)
4:15pm–4:35pm	Long term responses with vemurafenib and dabrafenib Axel Hauschild, MD (University Hospital Schleswig-Holstein, GER)
4:35pm–4:55pm	Melanoma resistance: defining the final common pathway Dirk Schadendorf, MD (University Hospital Essen, GER)
4:55pm–5:15pm	New therapeutic candidate targets Grant McArthur (Peter MacCallum Cancer Center,AUS)
5:15pm–5:35pm	Question &Panel Discussion All attendees
SUNday, OCT 23, 2016
Session 4: Local Therapy 　　　　Host: Prof. Liu Jiwei (Dalian Medical University Hospital,CHN) 　　　　　　　　Prof. Zhang Xiaoshi ( Sun Yat-Sen University Cancer Hospital,CHN)
8:00am–8:20am	Overview of oncolytic immunotherapy today Sanjiv Agarwala (Temple University School of Medicine, USA)
8:20am–8:40am	Oncolytic immunotherapies changing the path of tumor resistance Robert Andtbacka,MD (University of Utah, USA)
8:40am–9:00am	Novel topical therapy for melanoma in situ using an immune modulator XiaoweiXu, PhD (Hospital of University of Pennsylvania, USA)
Session 5: Acral & Mucosal Melanoma Forum 　　　　Host: Prof. Chen Xiaohong(Beijing Tongren Hospital) 　　　　　　　　Prof. Fan Yun(Cancer Hospital of Zhejiang Province)
9:00am-9:15am	Whole genome sequencing of acral melanoma Graham Mann,Ph.D(University of Sydney, AUS)
9:15am–9:30am	Whole genome sequencing of mucosal melanoma Yan Kong, PhD(Peking University Cancer Hospital, CHN)
9:30am-09:45am	Immunotherapy in mucosal melanoma Georgina Long, MD (University of Sydney, Melanoma Institute of Australia, AUS)
9:45am-10:00am	Clinical management of acral and mucosal melanoma Jun Guo (Peking University Cancer Hospital, CHN)
10:00am–10:15am	Clinical management of uveal and conjunctive melanoma Richard Carvajal, MD (Columbia University Medical Center, USA)
10:15am–10:30am	pathology in melanoma, including the tumor microenvironment on anti-PD1 Richard Scolyer, MD ( University of Sydney, Melanoma Institute of Australia, AUS )
10:30am–10:40am	Coffee & Tea
10:40am–10:50am	Experience and melanoma treatment in Taiwan Zhang Wenzhen, MD (Chang Gung Memorial Hospital, Taiwan,CHN)
10:50am–11:00am	Experience and melanoma treatment in Korea Sujin Lee, MD (Samsung Medical Center,Sungkyunkwan University, KOR)
11:00am–11:10am	Case Discussion 1: acral melanoma Lu Si, MD (Peking University Cancer Hospital &Institute, CHN)
11:10am–11:20am	Case Discussion 2: mucosal melanoma Anthony Ying, MD (Dr.Anthony C.H.Ying’ Clinic, Hong Kong, CHN)
Session 6: Oral Presentation 　　　　Host: Prof. Song Xin (Cancer Hospital of Yunnan Province,CHN) 　　　　　　　　Prof. Chi Zhihong (Peking University Cancer Hospital& Institute, CHN)
11:20am–11:26am	Five high quality trials are helping define the role of radiotherapy in melanoma Elizabeth Paton, MD( University of Technology, Sydney, NSW, Australia)
11:26am–11:32am	A prognostic model based on preoperative inflammatory markers for acral melanoma patients Rao Wang, MD (Sun Yat-Sen University Cancer Hospital,CHN)
11:32am–11:38am	The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from China Bin Lian, M.D ( Peking University Cancer Hospital &Institute,CHN)
11:38am–11:44am	Genotype and standard clinical features in 2793 melanomas Lili Mao, M.D ( Peking University Cancer Hospital &Institute,CHN)
11:44am–11:50am	PD-L1 Expression in Acral& Mucosal Melanoma and Its Clinical Significance Xue Bai, M.D ( Peking University Cancer Hospital &Institute,CHN)
11:50am–12:00am	Clinical Activity of Pembrolizumab in Chinese patients with melanoma Xizhi Wen, M.D (Sun Yat-Sen University Cancer Hospital,CHN)
12:00am–12:06am	OrienX010 Oncolytic Viral Therapy in Phase Ⅰb Trial of Intralesional Injection in Unresected Stage IIIC to IV Acral Melanoma Patients in China Chuanliang Cui,M.D ( Peking University Cancer Hospital &Institute,CHN)
12:06am–12:30am	Panel Discussion & Closing Remarks Jun Guo, MD, PhD (Peking University Cancer Hospital,CHN)